TXN and melanoma: Inhibition of glutathione synthesis via the GCLC inhibitor buthionine sulfoximine has not been shown to be effective against melanomas in vitro or in vivo; however, in combination with cysteine transport or thioredoxin inhibition, greater efficacy is achieved [52,122].